Generic drugs
The US Food and Drug Administration (FDA) has announced plans to simplify the development process for biosimilars, a type of medication that mimics complex biologic medicines. The proposed change would eliminate the need for lengthy clinical trials, allowing biosimilars to be approved more quickly. This move is expected to significantly
Chronic diseases
The U.S. Food and Drug Administration (FDA) has taken a major step to make biosimilar medicines more accessible and affordable for patients by streamlining the development process and reducing unnecessary clinical testing. This move aims to increase competition in the market and bring down the high costs associated with
Chronic diseases
The U.S. Food and Drug Administration (FDA) has taken a major step to make biosimilar medicines more accessible and affordable for patients by streamlining the development process and reducing unnecessary clinical testing. This move aims to increase competition in the market and bring down the high costs associated with
Generic drugs
Dr Reddy's Laboratories has received clearance from a subject expert committee to manufacture and market generic versions of semaglutide, a weight loss and obesity drug, in India. The company plans to launch the product as soon as the Danish drug maker Novo Nordisk's patent expires early
Epilepsy
A recent study has found that generic lacosamide (Stutan) has comparable efficacy, safety, and tolerability to its branded counterpart (Vimpat) in patients with focal or generalized epilepsy. The study, conducted at two epilepsy centers in Southern Italy, involved 60 adult patients who were divided into two groups: one receiving the
Tariffs
The US President's announcement on social media of a 100% tariff on "patented and branded" pharmaceutical imports has rattled pharma stocks in India, amid concerns that the scope could be expanded to include complex generics, biosimilars, and other advanced formulations. Top industry officials expressed concerns about
Tariffs
The US President's announcement of a 100% tariff on pharmaceutical products may not directly impact Indian pharmaceutical exports, as the measure targets "patented and branded products," while India predominantly ships generic drugs to the US. Indian authorities and industry experts have welcomed this move, citing that
Tariffs
India's pharmaceutical companies, known for manufacturing generic drugs, are unlikely to be significantly affected by US President Donald Trump's proposed 100 percent tariff on branded or patented pharmaceutical imports. However, experts have cautioned against making any assumptions, citing uncertainty in the definition of "branded"
Tariffs
The US President's plan to impose 100% tariffs on branded and patented pharmaceutical products may not have an immediate impact on Indian exports, with Indian pharmaceutical companies largely exporting generics to the US market. Indian Pharmaceutical Alliance (IPA) Secretary General Sudarshan Jain noted that the tariffs will not
Pharmaceutical industry
On World AIDS Day, President Obama acknowledged the critical role of treatment in preventing the spread of HIV/AIDS, citing new science that suggests antiretroviral treatment can reduce the risk of transmission by 96%. However, patent monopolies and high treatment costs for newer medicines threaten to undermine the progress made
Pharmaceutical industry
Ranbaxy Pharmaceuticals Inc., a subsidiary of Ranbaxy Laboratories Ltd., has received final approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Atorvastatin, the generic equivalent of Lipitor. This approval enables Ranbaxy to launch the product in the U.S. market, providing a safe, effective, and
Pharmaceutical industry
Glenmark Generics Inc., a subsidiary of Glenmark Generics Ltd, has received final approval from the US FDA for Norethindrone tablets 0.35mg, a generic version of Micronor tablets by Ortho McNeil Janssen Pharmaceuticals, Inc. This approval marks the company's third female hormonal product approval and second oral contraceptive
